Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With Obesity

This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.

开始日期2025-02-10

申办/合作机构

Novo Nordisk A/S

NCT06716307

/ Recruiting临床1期

Comparing the Pharmacokinetics of Cagrilintide and Semaglutide Following Single Subcutaneous Doses of Different CagriSema Presentations, in a Crossover Manner in Adult Participants With Overweight or Obesity

This study will compare the blood levels of cagrilintide and semaglutide when the same dose is given in two different versions of CagriSema. CagriSema is a medicine that combines two medicines called cagrilintide and semaglutide. It is still being tested in studies and is not yet available for doctors to prescribe. Participants will get an injection with each of the two versions of CagriSema at two different times at the clinic. Like all medicines, the study medicine may have side effects. The study will last for about 18 weeks.

开始日期2024-12-02

申办/合作机构

Novo Nordisk A/S

CTRI/2024/11/076345

/ Not yet recruiting临床2期

Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema 2.4mg or 2.4 mg) once weekly versus semaglutide 2.4 mg, cagrilintide 2.4 mg and placebo in people withchronic kidney disease and type 2 diabetes living with overweight or obesity - Nil

开始日期2024-11-18

申办/合作机构

Novo Nordisk India Pvt Ltd.

100 项与 CagriSema 相关的临床结果

登录后查看更多信息

100 项与 CagriSema 相关的转化医学

登录后查看更多信息

100 项与 CagriSema 相关的专利（医药）

登录后查看更多信息

1,220

项与 CagriSema 相关的文献（医药）

2025-01-07·Current cancer drug targets

WITHDRAWN: Network Pharmacology and In vitro Experiments Reveal that Noscapine Induces Ros-mediated Apoptosis and Cell Cycle Arrest via PI3K/Akt/FoxO3a Signaling Pathway in Human Bladder Cancer Cells

Article

作者: Chen, Lin ; Su, Yao ; Yang, Jin

Since the authors are not responding to the editor’s requests to fulfill the editorial requirement, therefore, the article has been withdrawn from the journal Current Cancer Drug Targets. Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused. The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience-com.libproxy1.nus.edu.sg/editorial-policies-main.php BENTHAM SCIENCE DISCLAIMER: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultane-ously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submit-ting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

2025-01-01·PHARMACOLOGICAL REVIEWS

Emerging pharmacotherapies for obesity: A systematic review

Article

作者: Al Rifai, Jana ; Valenzuela-Vallejo, Laura ; Rhayem, Caline ; Kokkorakis, Michail ; Mantzoros, Christos S ; Mantzoros, Christos S. ; Chakhtoura, Marlene ; Ghezzawi, Malak

The history of anti-obesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the conviction that excess body weight signifies a lack of willpower. However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/control or Food and Drug Administration-approved weight loss medication, through searching Medline, Embase, and ClinicalTrials.gov (2012-2024). We identified 53 phase 3 and phase 2 trials, with 36 emerging anti-obesity drugs or combinations thereof and four withdrawn or terminated trials. Oral semaglutide 50 mg is the only medication that has completed a phase 3 trial. There are 14 ongoing phase 3 trials on glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) (ecnoglutide, orforglipron, TG103), GLP-1 RA/amylin agonist (CagriSema), GLP-1/glucagon RAs (mazdutide, survodutide), GLP-1/glucose-dependent insulinotropic polypeptide and glucagon RA (retatrutide), dapagliflozin, and the combination sibutramine/topiramate. Completed phase 2 trials on incretin-based therapies showed a mean percent weight loss of 7.4-24.2%. Almost half of the drugs undergoing phase 2 trials were incretin analogs. The obesity drug pipeline is expanding rapidly, with the most promising results reported with incretin analogs. Data on mortality and obesity-related complications, such as cardio-renal-metabolic events, are needed. Moreover, long-term follow-up data on the safety and efficacy of weight maintenance with novel obesity pharmacotherapies, along with studies focused on under-represented populations, cost-effectiveness assessments, and drug availability, are needed to bridge the care gap for patients with obesity. Significance Statement Obesity is the epidemic of the 21st century. Except for the newer injectable medications, drugs with suboptimal efficacy have been available in the clinician's armamentarium. However, emerging alternatives of novel agents and combinations populate the obesity therapeutic pipeline. This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.

2024-10-01·Current diabetes reviews

Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity

Review

作者: Aliter, Hashem F. ; Al-Horani, Rami A. ; Aliter, Kholoud F.

Abstract::

Diabetes is a chronic illness that can become debilitating owing to its microvascular and macrovascular complications. Its prevalence is increasing and so is its cost. Diabetes, particularly type 2, appears to have a very close relationship with obesity. While lifestyle modifications, exercises, and current therapeutics have substantially improved clinical outcomes, the need for new therapeutics and regimens continue to exist. Several new medications and regimens for diabetes, obesity, and diabesity are showing promising results in advanced clinical trials. For type 1 diabetes mellitus (T1DM), they include teplizumab, ustekinumab, jakinibs, and cell therapies, whereas for type 2 diabetes mellitus (T2DM), they include once-weakly insulin, tirzepatide, high oral dose of semaglutide, orforglipron, retatrutide, CagriSema, and survodutide. Given their structural and mechanistic diversity as well as their substantial efficacy and safety profiles, these medications and regimens are paradigm shifting and promise a brighter future. They will likely enable better disease prevention and management. This review will provide details about each of the above strategies to keep the scientific community up to date about progress in the fields of diabetes and obesity

258

项与 CagriSema 相关的新闻（医药）

2025-01-28

·药智网

2025年有望上市的重磅新药TOP10

很大程度上，重磅创新药能否获批决定了药企未来的命运。例如，2024年Madrigal、Verona分别因其重磅新药Rezdiffra和Ohtuvayre的上市，取得亮眼业绩，声名鹊起。 2025年，FDA预计将批准更多新药上市，也将使更多药企将走到聚光灯下。例如罕见病传奇公司福泰制药或将斩获两款重磅新药，包括用于囊性纤维化的三联CFTR调节剂Alyftrek和止痛新药Suzetrigine，Evaluate预测这两款新药在2030年销售额将达到112亿美元。而Cytokinetics和Insmed是小型生物技术公司的佼佼者，有望推出其首个重磅炸弹药物。大型制药公司中，阿斯利康、赛诺菲、GSK、强生、礼来也或将在2025年收获重磅新药。表1 2025年有望上市的重磅新药TOP10 资料来源：Evaluate Pharma 1 福泰或成最大赢家从企业来看，福泰制药（Vertex）或成最大赢家，今年不仅有两款重磅炸弹有望上市，而且其囊性纤维化新一代三联疗法在2030年销售额预计将达到83亿美元，远超其他同期获批的新药。福泰制药以其治疗囊性纤维化的孤儿药起家，现在发展壮大为年营收百亿美元的大型生物技术公司。囊性纤维化（CF）是一种CFTR蛋白因基因突变而导致功能缺陷或丢失的遗传性疾病。针对CF的病因CFTR蛋白，福泰推出了Trikafta、Kalydeco、Orkambi和Symdeko系列产品，在CF领域几乎处于独占地位。目前，三代囊性纤维化组合疗法TRIKAFTA/KAFTRIO是福泰最主要的收入来源，尽管该药价格昂贵，但其在改善CF患者的肺功能和生活质量方面效果显著。2023年该药销售额89亿美元，2024年销售额预计将超过百亿美元。 2024年末，福泰的新一代三联疗法Alyftrek（简称Vanza三联疗法）获得FDA批准，用于治疗6岁及以上、携带至少一个F508del突变或其他对Alyftrek有反应的CFTR基因突变的囊性纤维化（CF）患者。该组合疗法中，Vanzacaftor和Tezacaftor旨在通过促进CFTR蛋白的加工和运输，增加细胞表面CFTR蛋白数量，而Deutivacaftor是旨在增加送达细胞表面的CFTR蛋白的通道开放概率，以改善细胞膜上盐和水的流动。Alyftrek每天一次给药，对31种额外突变有效，并且可以实现比Trikafta更强的降低汗液氯化物水平能力，是福泰在囊性纤维化领域的又一次成功迭代。福泰制药在2025年还有望迎来首个新机制的镇痛新药Suzetrigine（VX-548）。该药是一款选择性NaV1.8抑制剂，有望成为二十多年来首个用于治疗急性和神经性疼痛的新药。不过，不久前suzetrigine在2期坐骨神经痛（LSR）研究中虽然达到了主要终点，但降低疼痛的数字量表评分不及预期，可能会影响该药未来的销售峰值。除了福泰制药，GSK也将在2025年收获两个重磅新药：Depemokimab和MenABCWY。 Depemokimab（德莫奇单抗）是一款超长效IL-5单抗，仅需每半年注射一次。该药已于近日率先在中国提交上市申请，适应症包括重度嗜酸性粒细胞性哮喘（SEA）和慢性鼻-鼻窦炎伴鼻息肉（CRSwNP）。 MenABCWY是一款五价脑膜炎球菌ABCWY疫苗，结合已获批的脑膜炎疫苗Bexsero和Menveo的抗原成分，可针对五种脑膜炎球菌血清群（A，B，C，W和Y）的脑膜炎球菌保护接种者。该疫苗的BLA已获FDA受理，PDUFA日期为2025年2月14日。 2 GLP-1药物备受期待 GLP-1药物在过去两年的火爆程度有目共睹，今年中国市场或将迎来一款重磅新药：玛仕度肽。玛仕度肽（Mazdutide）是一款GLP-1R/GCGR双靶激动剂，原研为礼来，2019年信达生物引进其在中国的开发和商业化权益。据信达生物资料，该药高剂量9 mg组治疗48周，可减重17.8 kg，优于司美格鲁肽和替尔泊肽。图片来源：信达生物演示PPT 2024年2月，玛仕度肽首个NDA获受理，用于肥胖或超重患者长期体重管理，今年有望在中国获批上市。Evaluate预测其到2030年销售额将达13亿美元，虽然无法比肩超百亿美元的超级重磅炸弹，但对于中国药物市场，这已是一个相当可观的销售额。另外，诺和诺德和礼来都有新一代的GLP-1药物将在今年公布关键数据，或将改变该领域的竞争格局。诺和诺德的复方药物CagriSema，结合了司美格鲁肽与长效Amylin（胰淀素）类似物Cagrilintide两种药物，被给予厚望。其2期临床试验REDEFINE-1研究结果显示，治疗68周，CagriSema组体重减轻22.7%（基于试验产品估算）或20.4%（基于治疗政策估算），与礼来的替尔泊肽相当（72周治疗方案估算为22.5%或20.9%）。如果借助优先审评券，该药或许有望在2025年获批。礼来的Retatrutide是一款GLP-1/GIP/GCG三受体激动剂，已启动3期临床研究。其全球2期临床试验表明，在超重或肥胖人群中，Retatrutide 4、8、12 mg每周1次治疗48周时平均减重分别为17.1%、22.8%、24.2%，疗效或将超越替尔泊肽。礼来另一个GLP-1管线orforglipron也备受期待。该药是一款小分子非肽类GLP-1RA口服制剂，给药频率为每日一次。其2期临床数据显示，治疗36周，45mg剂量组减重14.7%，相较安慰剂组减重12.4%。作为GLP-1R小分子赛道的领头羊，让人们对其今年有望公布的3期临床数据充满了期待。 3 更多重磅药物即将登场今年有望获批的重磅药物中还有第一三共与阿斯利康联合开发的Trop2 ADC、Cytokinetics公司的心脏病新药及多款自免新药。 Datopotamab Deruxtecan Datopotamab Deruxtecan（Dato-DXd）是一款靶向TROP2的ADC药物，也是第一三共和阿斯利康合作推出的第二款ADC，两家公司曾联合推出ADC明星产品德曲妥珠单抗，因此该药备受期待。该药已于2024年12月在日本获批，用于治疗既往接受过化疗的成年人HR阳性、HER2阴性不可切除或复发乳腺癌患者，商品名Datroway。2025年1月，该药又在美国获批用于治疗乳腺癌。不过，2024年12月，阿斯利康基于TROPION-Lung01Ⅲ期试验的结果，自愿撤回了在欧盟提交的Dato-DXd肺癌适应症上市申请，具体适应症为局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）成年患者。但这并不意味着该药在肺癌领域的失败，不久后，阿斯利康又在美国提交了Dato-DXd治疗经治局部晚期或转移性表皮生长因子受体突变（EGFRm）非小细胞肺癌成年患者的上市申请，并获得优先审评资格，FDA预计将在2025年第三季度完成审评。 Aficamten Aficamten是一款新一代选择性小分子心肌肌球蛋白ATP酶抑制剂，由Cytokinetics公司研发。2024年10月，NMPA已受理aficamten片用于治疗梗阻性肥厚型心肌病（oHCM）的新药上市申请并将其纳入优先审评品种。2024年12月，FDA也受理了aficamten用于治疗oHCM的新药申请，PDUFA日期为2025年9月26日。Evaluate预测其销售额在2030年将达到28亿美元。 Tolebrutinib Tolebrutinib是赛诺菲开发的一种口服、能穿越血脑屏障的BTK抑制剂，正在准备向监管机构递交上市申请，此前该药已获FDA突破性疗法认定，用于治疗患有非复发性继发进展型多发性硬化（nrSPMS）的成年患者。近年，BTK用于自免疾病成为市场关注的焦点，tolebrutinib能获得突破性疗法认定，意味着其在临床重要终点上的疗效较现有药物有显著改善。 Brensocatib Brensocatib是一种口服、可逆性DPP1小分子抑制剂，拟用于治疗支气管扩张症。该药正在准备向监管机构递交上市申请，此前已获得美国FDA授予的突破性疗法认定，用于治疗非囊性纤维化支气管扩张。如果获得批准，brensocatib将成为首个获批治疗支气管扩张症的药物，预期其销售额在2030年将超过10亿美元。 Nipocalimab Nipocalimab是一款FcRn单抗，来自强生以65亿美元从Momenta公司引进，具有治疗多种自身免疫疾病的潜力。自免领域向来重磅产品迭出，而现在又处于新老产品交替之际，该药有望成为强生自免领域的新一代重磅产品。友情推荐：医药行业深度技术内容，点击“博药”查看详情~ 声明：本内容仅用作医药行业信息传播，为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 小月石合作、投稿、转载开白 | 马老师 18323856316（同微信）阅读原文，是受欢迎的文章哦

孤儿药上市批准临床研究医药出海

2025-01-28

·PRNewswire

Novo Nordisk A/S Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO

NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2, 2022 and December 19, 2024. Follow the link below to get more information and be contacted by a member of our team: NVO investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, on December 20, 2024, Novo issued a press release announcing the below-expected results of their "REDEFINE 1" trial, "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release further indicated that participant patients were permitted to modify their own dosage during the trial and, as a result, only 57.3% of patients treated with CagriSema were on the highest dosage contemplated by the study. Following this news, Novo's stock price fell by $18.44 per share to close at $85.00 per share. WHAT'S NEXT? If you suffered a loss in Novo during the relevant time frame, you have until March 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 SOURCE Levi & Korsinsky, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果专利侵权

2025-01-26

·药明康德

从肿瘤到AI：2025年全球医药发展的关键趋势

▎药明康德内容团队编辑 2025年，全球医药领域将迎来一系列重要趋势和突破性进展。在肿瘤学、肥胖症药物以及人工智能（AI）应用的推动下，药物创新的格局正在被重新塑造，医疗健康产业也将面临前所未有的机遇与挑战。近期，《自然》旗下的Nature Reviews Drug Discovery针对这些关键议题进行了深入分析，美国癌症研究协会（AACR）也邀请专家展望2025年癌症领域的潜在进展。基于这些洞察，药明康德内容团队将与读者一起深入探讨2025年医药研发的未来发展方向。图片来源：123RF 癌症领域关于2025年癌症领域的发展，玛格丽特公主癌症中心的资深医学肿瘤学家Lillian Siu博士表示，我们正步入一个通过靶向特定突变的下一代分子攻克“不可成药”靶点的全新时代。她指出，尽管第一代KRAS G12C抑制剂（如Lumakras和Krazati）已经成功上市，RAS领域的研究仍然十分活跃。产业界不仅在积极开发第二代KRAS G12C抑制剂，同时也在推进针对KRAS G12D、KRAS G12V、泛KRAS以及泛RAS抑制剂的早期1期临床试验。除了小分子抑制剂之外，治疗性癌症疫苗和T细胞受体疗法等新型治疗手段也在积极探索中，进一步扩展了靶向KRAS致癌基因的治疗可能性。癌症疫苗领域有望在2025年迎来重要突破。FDA预计将批准首款个体化癌症疫苗——Moderna的mRNA-4157联合默沙东（MSD）的PD-1抑制剂Keytruda（pembrolizumab）用于黑色素瘤的治疗。这一创新疗法的获批可能彻底改变癌症治疗的格局。同时，双特异性抗体的最新进展也备受关注。在非小细胞肺癌（NSCLC）领域，靶向PD-1和VEGF的双特异性抗体ivonescimab展现出潜在“first-in-class”疗法的强大潜力。作为一线治疗，该药在PD-L1阳性晚期NSCLC患者中显著降低了疾病进展或死亡的风险。目前，全球范围内的临床试验正在积极推进，ivonescimab有望成为新的治疗标准。此外，双特异性抗体Ziihera（zanidatamab）也在2024年11月获得FDA批准，用于治疗胆道癌。作为首款能够同时结合同一靶点（HER2）两个表位的双特异性抗体，该药预计将在2025年惠及更多患者，为相关疾病的治疗带来新的希望。图片来源：123RF 此外，产业界在给药方式的优化上也取得了重要进展。2024年9月，FDA批准了罗氏（Roche）的PD-L1抑制剂Tecentriq（atezolizumab）的皮下注射制剂，紧随其后，12月又批准了百时美施贵宝（Bristol Myers Squibb）的PD-1抑制剂Opdivo（nivolumab）的皮下注射制剂。同时，Keytruda的皮下注射制剂在去年完成了3期临床试验并取得积极结果，预计不久后将获批上市。这些新型制剂的推出，不仅为患者提供了更便捷的治疗选择，还显著提升了整体治疗体验，为癌症治疗带来了新的可能性。 2025年，另一个持续发展的重要趋势是对新辅助治疗临床试验的关注度不断提升，特别是基于免疫疗法或已在其他癌症类型中显示出积极疗效的靶向治疗的试验。这些研究有望为患者提供更多创新的治疗选择，进一步改善治疗效果和预后。减重领域 2025年，减重领域将迎来多项备受瞩目的临床试验结果。其中，包括礼来（Eli Lilly and Company）的GIP/GLP-1受体双重激动剂tirzepatide在2型糖尿病患者中进行的心血管结局3期研究（SURPASS-CVOT）的数据，以及口服司美格鲁肽（semaglutide）在早期阿尔茨海默病患者中评估其对认知和功能影响的EVOKE和EVOKE+试验结果，这些成果可能为治疗肥胖和相关疾病提供重要的新方向。参考阅读：2025年值得关注的10余项减重疗法临床试验同时，多种新分子的3期临床数据也备受关注。礼来的orforglipron有望成为首款上市的口服GLP-1受体小分子激动剂，这一突破将显著改变肥胖治疗的格局。据行业媒体Endpoints News报道，目前只有司美格鲁肽和orforglipron两种GLP-1口服疗法进入了肥胖领域的3期试验。此外，诺和诺德（Novo Nordisk）的CagriSema（由长效胰淀素类似物cagrilintide和司美格鲁肽组成）正在针对超重或肥胖的2型糖尿病患者开展两项重要3期临床试验——REDEFINE-2试验预计在2025年上半年公布初步数据，而与礼来减重疗法Zepbound直接对比的REDEFINE-4试验则预计在下半年公布结果。图片来源：123RF 此外，Metsera旗下每月一次的超长效皮下注射GLP-1受体激动剂MET-097i，也在针对肥胖或超重患者的2b期试验中取得进展，目前已完成入组，顶线数据预计将在2025年中期发布。这些重要的研究和新药进展将进一步推动肥胖治疗领域的创新发展，为患者带来更多选择和新的希望。人工智能领域 2025年，AI工具的能力和应用预计将继续快速增长。随着算法效率、硬件性能和训练数据可用性的持续提升，AI的计算性能有望在未来一年内至少翻倍，这将显著增强其在生物学和医学预测中的应用潜力。在癌症领域，AI的发展前景尤为引人关注。麻省理工学院的Regina Barzilay博士及其团队的研究表明，AI在预测癌症未来发展轨迹方面表现卓越，准确性可与人类专家媲美。这一能力有望带来两大突破：一是帮助识别需要更频繁筛查的高风险人群；二是发现适合参与化疗预防试验的潜在患者，从而推动新的癌症预防疗法的开发，这些试验此前因难以有效筛选目标人群而进展受限。与此同时，AI在癌症研究中的应用正从传统的影像学和病理学扩展到分子建模等更深层次的领域。通过结合多年积累的实验数据和开放资源（如人类细胞图谱），研究人员能够利用AI更精确地表征细胞状态和行为。随着血液分析、影像学、细胞测序等多模态生物数据的整合分析逐渐实现，AI将为癌症诊断和治疗提供全新的视角和更强大的工具。例如，正在进行的ADAPT项目探索通过追踪肿瘤在多轮治疗中的变化来预测其突变路径，并制定个体化治疗方案，为临床和研究提供关键数据支持。尽管如此，由于生物系统的高度复杂性，从分子层面延伸到细胞或人体层面的预测依然面临重大挑战。因此，尽管未来可能会有更多由AI发现的分子进入临床试验，但AI在临床证据生成领域的应用速度可能较为缓慢。此外，由于预测患者结果的复杂性以及欧洲即将实施的AI监管，AI在药物研发中的广泛应用与临床环境中的逐步推广之间可能会出现显著分化。图片来源：123RF 展望2025年，医药行业将在癌症治疗、肥胖症药物和人工智能应用等领域取得突破，这些进展将为患者带来更多希望。尽管面临临床转化和资源可及性的挑战，全球协作和对创新的共同追求将推动技术和药物更快惠及患者。让我们期待，2025年的创新能为更多患者带来健康福音，开启医疗未来的新篇章。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] Rickwood S, Bayley H, Lutzmayer S, Madelung M, Gores M. Outlook for medicines development and use in 2025. Nat Rev Drug Discov. 2025 Jan 15. doi: 10.1038/d41573-025-00012-2. Epub ahead of print. PMID: 39814988. [2] Experts Forecast Cancer Research and Treatment Advances in 2025. Retrieved January 25, 2025 from https://www-aacr-org.libproxy1.nus.edu.sg/blog/2025/01/10/experts-forecast-cancer-research-and-treatment-advances-in-2025/ 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

AACR会议疫苗临床3期信使RNA临床结果

100 项与 CagriSema 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床3期	保加利亚	Novo Nordisk Pharmaceuticals Pty Ltd.	2023-09-27
2型糖尿病	临床3期	哥伦比亚	Novo Nordisk Pharmaceuticals Pty Ltd.	2023-09-27
2型糖尿病	临床3期	克罗地亚	Novo Nordisk Pharmaceuticals Pty Ltd.	2023-09-27
2型糖尿病	临床3期	捷克	Novo Nordisk Pharmaceuticals Pty Ltd.	2023-09-27
2型糖尿病	临床3期	丹麦	Novo Nordisk Pharmaceuticals Pty Ltd.	2023-09-27
2型糖尿病	临床3期	芬兰	Novo Nordisk Pharmaceuticals Pty Ltd.	2023-09-27
2型糖尿病	临床3期	墨西哥	Novo Nordisk Pharmaceuticals Pty Ltd.	2023-09-27
2型糖尿病	临床3期	斯洛文尼亚	Novo Nordisk Pharmaceuticals Pty Ltd.	2023-09-27
2型糖尿病	临床3期	韩国	Novo Nordisk Pharmaceuticals Pty Ltd.	2023-09-27
2型糖尿病	临床3期	瑞典	Novo Nordisk Pharmaceuticals Pty Ltd.	2023-09-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EASD2023	N/A	-	-	CagriSema	觸襯艱窪鬱簾廠膚顧蓋(顧襯蓋鑰壓鏇齋鹹憲範) = 鑰網積鹹觸憲鹽願鹹選選淵淵壓簾遞遞遞製選 (選構獵廠鹹鏇膚製願積 ) 更多	积极	2023-10-03
				Cagrisema (Weight matched group (WM))	觸襯艱窪鬱簾廠膚顧蓋(顧襯蓋鑰壓鏇齋鹹憲範) = 鬱膚衊築衊鏇夢廠繭鏇選淵淵壓簾遞遞遞製選 (選構獵廠鹹鏇膚製願積 )
NAASO2022	N/A	-	-	Vehicle control	鬱餘齋觸繭製膚糧糧憲(窪簾網窪選廠醖廠醖齋) = 齋製願獵構觸淵構夢選築壓築鑰廠願蓋鹽窪鑰 (艱艱鏇築鑰壓蓋壓願窪 ) 更多	-	2022-11-21
				CagriSema	鬱餘齋觸繭製膚糧糧憲(窪簾網窪選廠醖廠醖齋) = 醖願鬱遞壓顧窪選繭顧築壓築鑰廠願蓋鹽窪鑰 (艱艱鏇築鑰壓蓋壓願窪 ) 更多